Open AccessEvidence for risk stratification when monitoring for toxicities following initiation of combination antiretroviral therapy
Author(s) -
Babafemi Taiwo,
Elizabeth L. Yanik,
Sonia Napravnik,
Patrick Ryscavage,
Susan L. Koletar,
Richard D. Moore,
W. Christopher Mathews,
Heidi M. Crane,
Kenneth H. Mayer,
Anne Zinski,
James S. Kahn,
Joseph J. Eron
Publication year - 2013
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e3283601115
Subject(s) - antiretroviral therapy , risk stratification , medicine , antiretroviral agents , sida , human immunodeficiency virus (hiv) , intensive care medicine , oncology , virology , viral disease , viral load
Laboratory monitoring is recommended during combination antiretroviral therapy (cART), but the pattern of detected abnormalities and optimal monitoring are unknown. We assessed laboratory abnormalities during initial cART in 2000-2010 across the United States.